Ambryon Biosciences

Artificial intelligence and the transformation of cell and gene therapy development

Auclair et al. (2026). Pharmaceutics·Citations: 8Review

Cell and gene therapy construct design still means building and testing large variant libraries, and bespoke manufacturing limits access. This review maps AI across that lifecycle, from generative design to digital-twin manufacturing.

Key findings

  • Machine learning shifts viral vector engineering toward generative design, predicting tropism and immunogenicity from capsid sequence, optimizing promoter, codon usage and regulatory elements for transgene expression, and proposing novel capsid variants with better tissue specificity and lower immunogenicity.

  • AI-enabled cell and gene therapy depends on infrastructure and people as much as models: it requires investment in digital infrastructure and a workforce combining biomanufacturing and data science skills, HIPAA and GDPR compliance.

  • A Design-Build-Test-Learn loop embeds computational modelling in construct engineering, with in silico design and prediction at DNA, mRNA and protein levels, and experimental results feeding back through active learning so each cycle is more accurate.

  • Machine learning on historical batch data, including initial cell quality, donor characteristics and media components, can predict final cell yield and optimal harvest timing in CAR-T manufacturing, while digital twins tracking vein-to-vein journeys monitor location, temperature and integrity.

Author abstract

Cell and Gene Therapy (CGT) represents a paradigm shift in medicine, offering curative potential for previously intractable diseases. However, the complexity, high cost, and manufacturing challenges inherent in developing, producing, and administering these therapies hinder their widespread accessibility. This review examines the critical and increasingly synergistic role of Artificial Intelligence (AI) and Machine Learning (ML) in overcoming these barriers across the entire CGT lifecycle, from discovery and construct design to smart manufacturing, clinical translation, and regulatory applications. We analyze how AI-driven approaches fundamentally differ from conventional methods, facilitating rapid construct optimization, generating highly predictive translational models, enabling the vision of autonomous, digital-twin-driven manufacturing, and establishing new paradigms for pharmacovigilance and regulatory oversight. The integration of AI is not merely an incremental improvement but a foundational transformation, positioning CGT to move from niche, bespoke treatments to scalable, accessible, and highly personalized medical modalities. We conclude by discussing current gaps, particularly data scarcity and regulatory uncertainty, and outlining a roadmap to realize the full potential of AI-enabled CGT.

Identifiers & revision